Literature DB >> 6870607

Paraldehyde therapy in childhood status epilepticus.

R G Curless, B H Holzman, R E Ramsay.   

Abstract

Intravenous (IV) diazepam or phenobarbital is generally accepted as the initial treatment of choice for status epilepticus in children. The risk of severe respiratory depression with either drug is a major problem, particularly in emergency centers that do not have appropriate equipment or personnel for rapid endotracheal intubation of infants. While some pediatric centers are not reluctant to recommend paraldehyde for secondary therapy in status epilepticus, most texts and publications recommend it only as a last resort because of reported complications. We investigated the benefits and complications from varied dosing regimens in 16 trials. The results indicated no significant complications in patients who did not receive an initial IV bolus. Even though treatment with phenobarbital or diazepam and phenytoin sodium had failed, 37% had a good therapeutic response.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6870607     DOI: 10.1001/archneur.1983.04210070017006

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  4 in total

Review 1.  Treatment of status epilepticus in children.

Authors:  M De Negri; M G Baglietto
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 2.  An approach to respiratory distress and central nervous system emergencies.

Authors:  N Kissoon; D Vidyasagar
Journal:  Indian J Pediatr       Date:  1991 Mar-Apr       Impact factor: 1.967

Review 3.  The treatment of convulsive status epilepticus in children. The Status Epilepticus Working Party, Members of the Status Epilepticus Working Party.

Authors:  R Appleton; I Choonara; T Martland; B Phillips; R Scott; W Whitehouse
Journal:  Arch Dis Child       Date:  2000-11       Impact factor: 3.791

Review 4.  Guidelines for stabilizing the condition of the critically ill child before transfer to a tertiary care facility.

Authors:  J B Kronick; N Kissoon; T C Frewen
Journal:  CMAJ       Date:  1988-08-01       Impact factor: 8.262

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.